After reports of Narsingh Yadav failing doping test surfaced on Sunday, his roommate Sandeep Yadav, in a latest development, has also been reported to have failed the test conducted by the National Anti-Doping Agency (NADA). 
 
The two wrestlers are roommates at the Sports Authority of India, Sonepat, according to zeenews.com. Narsingh, who tested positive for a banned steroid in the &#39;B&#39; sample, appeared in front of the NADA disciplinary panel on Saturday. Both of them tested positive in methandienone, an anabolic steroid, the tests of which were conducted on June 25.
<div class="twitter-block">
<blockquote class="twitter-tweet" data-lang="en">
I am doing so well, why would I even take banned steroids? : Narsingh Yadav
&mdash; ANI (@ANI_news) <a href="https://twitter.com/ANI_news/status/757489324447371264">July 25, 2016</a></blockquote>
<script async src="~/platform.twitter.com/widgets.js" charset="utf-8" type="text/javascript"></script></div>
 
While Narsingh had won a long legal battle against Sushil Kumar to be a part of Rio 2016 squad, Sandeep was not selected in the Indian contingent. Narsingh&#39;s Rio dreams, however, look over as the Indian Olympic Association (IOA) have reportedly withheld his accreditation card. 
&nbsp;
<div class="twitter-block">
<blockquote class="twitter-tweet" data-lang="en">
I should be sent to Rio Olympics and hope this will be sorted out soon. I have written to federation,want justice: Narsingh Yadav
&mdash; ANI (@ANI_news) <a href="https://twitter.com/ANI_news/status/757490070966378496">July 25, 2016</a></blockquote>
<script async src="~/platform.twitter.com/widgets.js" charset="utf-8" type="text/javascript"></script></div>
 
 
 
The WFI team has postponed their preparatory camp trip to Georgia, which was supposed to leave on Monday. If found guilty, Narsingh&#39;s absence at Rio will be a huge blow to India as the final date to send the list of athletes participating in Olympics was July 18, leaving no chance for a replacement in the 74 kilogram category. 
 
(DNA)

Sandeep can't make it to Rio anyway, but his roommate Narsingh's Olympics hopes appear to be over

After reports of Narsingh Yadav failing doping test surfaced on Sunday, his roommate Sandeep Yadav, in a latest development, has also been reported to have failed the test conducted by the National Anti-Doping Agency (NADA). The two wrestlers are roommates at the Sports Authority of India, Sonepat, according to zeenews.com. Narsingh, who tested positive for a banned steroid in the 'B' sample, appeared in front of the NADA disciplinary panel on Saturday. Both of them tested positive in methandienone, an anabolic steroid, the tests of which were conducted on June 25. I am doing so well, why would I even take banned steroids? : Narsingh Yadav — ANI (@ANI_news) July 25, 2016 While Narsingh had won a long legal battle against Sushil Kumar to be a part of Rio 2016 squad, Sandeep was not selected in the Indian contingent. Narsingh's Rio dreams, however, look over as the Indian Olympic Association (IOA) have reportedly withheld his accreditation card. I should be sent to Rio Olympics and hope this will be sorted out soon. I have written to federation,want justice: Narsingh Yadav — ANI (@ANI_news) July 25, 2016 The WFI team has postponed their preparatory camp trip to Georgia, which was supposed to leave on Monday. If found guilty, Narsingh's absence at Rio will be a huge blow to India as the final date to send the list of athletes participating in Olympics was July 18, leaving no chance for a replacement in the 74 kilogram category. (DNA)

Wrestlers Narsingh and Sandeep Yadav both fail Olympic doping test

British Labour Party lawmakers voted massively against their leader on Tuesday amid political turmoil in Britain after a vote to leave the European Union, as candidates to succeed Prime Minister David Cameron vied for power behind the scenes. 
 
Labour&#39;s Jeremy Corbyn lost a non-binding confidence motion, with 172 Labour MPs voting against him and only 40 in favour out of a total of 229 Labour lawmakers in the House of Commons lower house. But the veteran socialist insisted he would not stand down. 
 
&quot;I was democratically elected leader of our party for a new kind of politics by 60 per cent of Labour members and supporters, and I will not betray them by resigning. Todays vote by MPs has no constitutional legitimacy,&quot; he said in a statement. 
 
Five days after the shock referendum vote, the two parties that have dominated Westminster for nearly a century were in almost complete disarray. 
 
Pro-EU finance minister George Osborne, long tipped to succeed Cameron, ruled himself out on Tuesday while British media reported that Work and Pensions Minister Stephen Crabb, a virtual unknown to the British public, would put his name forward. 
 
Former London mayor and &quot;Leave&quot; figurehead Boris Johnson -- now a bogeyman for many in the &quot;Remain&quot; camp -- is tipped as one of the favourites. 
 
The other is interior minister Theresa May who is reportedly seeking support for a rival bid that British media tipped as the &quot;Stop Boris&quot; campaign. 
 
The Conservatives have set a Thursday deadline for nominations, and the party said the winner would be announced on September 9. 
 
Cameron has said he would leave it to his successor to invoke Article 50 -- the formal procedure for exiting the European Union.On the opposition side, over half of Corbyns shadow cabinet -- the leadership of his party -- have now resigned since Sunday in a coordinated series of resignations against the 67-year-old, who only became leader in September. 
 
Corbyn, a veteran socialist and eurosceptic who voted against EU membership in a 1975 referendum, has come under heavy criticism from pro-EU lawmakers for his lukewarm campaigning in favour of Britain staying in. Many experts have blamed the strong anti-EU vote in Labour heartlands in northern England on Corbyn. 
 
But Corbyn himself has blamed Conservative austerity measures for creating disenchantment in many working-class areas, and said the media had not covered Labours referendum campaign, focussing instead on rifts within the ruling Conservatives. 
 
The Conservatives are meanwhile scrambling to choose a successor to Cameron, who announced his resignation within hours of the Brexit result last Friday. 
 
A new poll Tuesday put May in the lead with 31 per cent, against 24 per cent for Johnson. 
 
Nominations for the party leadership open Wednesday, and close Thursday. 
 
If more than two candidates stand, Tory MPs will vote next week to whittle down the field to two nominees, before the new leader is chosen by a postal ballot of party members, who currently number around 150,000. 
 
The new Tory leader is expected to be announced on September 9, the party announced Tuesday. 
 
Critics have questioned whether the &quot;Leave&quot; camp -- and Johnson in particular -- has any idea how to manage the unprecedented situation left by last week&#39;s vote. 
 
&quot;He has still to offer anything like a concrete plan on how he would negotiate the post-Brexit future,&quot; wrote former BBC political editor Nick Robinson. 
 
He added: &quot;The fallout from the biggest exercise in popular democracy has already been dramatic... It has, though, only just begun.&nbsp;The old order has been smashed. It may be a very long time -- not weeks, not months but years -- before the shape of the new order and the answers to all those questions become clear.&quot; 
 
(AFP)

Actually, both major British parties are in disarray after last week's decision to leave the EU

British Labour Party lawmakers voted massively against their leader on Tuesday amid political turmoil in Britain after a vote to leave the European Union, as candidates to succeed Prime Minister David Cameron vied for power behind the scenes. Labour's Jeremy Corbyn lost a non-binding confidence motion, with 172 Labour MPs voting against him and only 40 in favour out of a total of 229 Labour lawmakers in the House of Commons lower house. But the veteran socialist insisted he would not stand down. "I was democratically elected leader of our party for a new kind of politics by 60 per cent of Labour members and supporters, and I will not betray them by resigning. Todays vote by MPs has no constitutional legitimacy," he said in a statement. Five days after the shock referendum vote, the two parties that have dominated Westminster for nearly a century were in almost complete disarray. Pro-EU finance minister George Osborne, long tipped to succeed Cameron, ruled himself out on Tuesday while British media reported that Work and Pensions Minister Stephen Crabb, a virtual unknown to the British public, would put his name forward. Former London mayor and "Leave" figurehead Boris Johnson -- now a bogeyman for many in the "Remain" camp -- is tipped as one of the favourites. The other is interior minister Theresa May who is reportedly seeking support for a rival bid that British media tipped as the "Stop Boris" campaign. The Conservatives have set a Thursday deadline for nominations, and the party said the winner would be announced on September 9. Cameron has said he would leave it to his successor to invoke Article 50 -- the formal procedure for exiting the European Union.On the opposition side, over half of Corbyns shadow cabinet -- the leadership of his party -- have now resigned since Sunday in a coordinated series of resignations against the 67-year-old, who only became leader in September. Corbyn, a veteran socialist and eurosceptic who voted against EU membership in a 1975 referendum, has come under heavy criticism from pro-EU lawmakers for his lukewarm campaigning in favour of Britain staying in. Many experts have blamed the strong anti-EU vote in Labour heartlands in northern England on Corbyn. But Corbyn himself has blamed Conservative austerity measures for creating disenchantment in many working-class areas, and said the media had not covered Labours referendum campaign, focussing instead on rifts within the ruling Conservatives. The Conservatives are meanwhile scrambling to choose a successor to Cameron, who announced his resignation within hours of the Brexit result last Friday. A new poll Tuesday put May in the lead with 31 per cent, against 24 per cent for Johnson. Nominations for the party leadership open Wednesday, and close Thursday. If more than two candidates stand, Tory MPs will vote next week to whittle down the field to two nominees, before the new leader is chosen by a postal ballot of party members, who currently number around 150,000. The new Tory leader is expected to be announced on September 9, the party announced Tuesday. Critics have questioned whether the "Leave" camp -- and Johnson in particular -- has any idea how to manage the unprecedented situation left by last week's vote. "He has still to offer anything like a concrete plan on how he would negotiate the post-Brexit future," wrote former BBC political editor Nick Robinson. He added: "The fallout from the biggest exercise in popular democracy has already been dramatic... It has, though, only just begun. The old order has been smashed. It may be a very long time -- not weeks, not months but years -- before the shape of the new order and the answers to all those questions become clear." (AFP)

Corbyn fights to maintain grip on Labour party after Brexit vote

Mice given a single shot of one of two experimental Zika vaccines were completely protected when exposed to the virus one to two months later, a promising sign that similar vaccines under development for humans will protect against Zika, US researchers said on Tuesday. 
 
&ldquo;This is an encouraging first step in Zika vaccine design and pre-clinical testing. This new mouse model should be useful for comparative assessments of the large range of vaccine candidates now being designed,&quot; said Professor Adrian Hill, director of Oxford University&#39;s Jenner Institute, which did not conduct the mouse study but is also developing Zika vaccines. 
 
Separately, US scientists said they have developed a model of the Zika virus in monkeys, a close proxy for human disease. 
 
The studies advance efforts in fighting the mosquito-borne Zika virus, which has swept through the Americas and Caribbean since last fall, and has been linked to thousands of cases of microcephaly, a rare birth defect, in Brazil, as well as to neurological disorders. On February 1, the World Health Organization declared Zika a global health emergency. 
 
&ldquo;With diseases spread by biting insects, such as Zika, standard quarantine measures are useless, so stopping an outbreak in its tracks requires a vaccine-led approach,&quot; said Dr Derek Gatherer, a lecturer in the division of biomedical and life sciences at Britain&#39;s Lancaster University. 
 
In the mouse study, published in the journal Nature, a team led by Dr Dan Barouch of Beth Israel Deaconess Medical Center and Harvard Medical School, tested two different vaccine candidates in a strain of mice that develops Zika symptoms. 
 
One candidate, a DNA vaccine, was developed by Barouch and colleagues. It contains bits of genetic material from a Zika virus strain from Brazil. 
 
The other was made from a purified but inactivated version of the Zika virus from Puerto Rico. That vaccine was developed by researchers at Walter Reed Army Institute of Research in Silver Spring, Maryland. 
 
Mice given either type of vaccine were 100 per cent protected from Zika after a single shot. Unvaccinated mice that were exposed to the virus all developed symptoms of Zika. 
 
Both types of vaccines - DNA and inactivated virus vaccines - have been successfully developed to prevent infection from viruses related to Zika, including West Nile and dengue. 
 
The team also showed that antibodies taken from immunized mice could be used to protect other, unvaccinated mice, offering proof that the antibodies produced by the vaccines were specific to Zika. 
 
&quot;We need to be cautious about extrapolating data from a mouse model into humans,&quot; Barouch said. But the fact that the vaccines protected mice and that their antibodies protected other mice from Zika was grounds for optimism over the development of a Zika vaccine, he said. 
 
At least 15 companies and academic groups are racing to develop Zika vaccines, according to the WHO. US vaccine maker Inovio Pharmaceuticals last week got US Food and Drug Administration approval to begin testing its Zika DNA vaccine in humans. 
 
Oxford University&#39;s Hill stressed that there are still years of testing needed before a finished vaccine will be available for humans. 
 
MONKEY INFECTION 
 
In another advance, researchers at the University of Wisconsin reported on Tuesday that they have successfully infected rhesus macaques with an Asian strain of the Zika virus that is currently circulating in the Americas. The study, published in the journal Nature Communications, shows that monkeys - which have immune responses similar to humans - can be used to study Zika. 
 
In the study, David O&#39;Connor and colleagues inoculated eight rhesus macaques - including two pregnant monkeys - with a strain of Zika virus currently circulating in the Americas. 
 
All eight animals were infected. Tests showed viral particles in their blood, saliva, urine and spinal fluid. All animals stayed infected for at least 21 days, and some remained infected for at least 57 days. 
 
A second exposure to Zika 10 weeks after the first did not make the animals sick, suggesting that antibodies developed by the monkeys protected them against a second case of Zika. This is a promising sign that humans may similarly be able to develop protective antibodies against the virus. 
 
The scientists are still working to understand whether the pregnant monkeys will pass the infection along to their fetuses, and whether infected monkeys can transmit the virus sexually, as has been seen in infected humans. 
 
US health officials have concluded that Zika infections in pregnant women can cause microcephaly, a birth defect marked by small head size that can lead to severe developmental problems in babies. The WHO has said there is strong scientific consensus that Zika can also cause Guillain-Barre, a rare neurological syndrome that causes temporary paralysis in adults. 
 
(Reuters)

Encouraging tests have been conducted on both mice and monkeys, but it'll be years before humans have a finished Zika vaccine

Mice given a single shot of one of two experimental Zika vaccines were completely protected when exposed to the virus one to two months later, a promising sign that similar vaccines under development for humans will protect against Zika, US researchers said on Tuesday. “This is an encouraging first step in Zika vaccine design and pre-clinical testing. This new mouse model should be useful for comparative assessments of the large range of vaccine candidates now being designed," said Professor Adrian Hill, director of Oxford University's Jenner Institute, which did not conduct the mouse study but is also developing Zika vaccines. Separately, US scientists said they have developed a model of the Zika virus in monkeys, a close proxy for human disease. The studies advance efforts in fighting the mosquito-borne Zika virus, which has swept through the Americas and Caribbean since last fall, and has been linked to thousands of cases of microcephaly, a rare birth defect, in Brazil, as well as to neurological disorders. On February 1, the World Health Organization declared Zika a global health emergency. “With diseases spread by biting insects, such as Zika, standard quarantine measures are useless, so stopping an outbreak in its tracks requires a vaccine-led approach," said Dr Derek Gatherer, a lecturer in the division of biomedical and life sciences at Britain's Lancaster University. In the mouse study, published in the journal Nature, a team led by Dr Dan Barouch of Beth Israel Deaconess Medical Center and Harvard Medical School, tested two different vaccine candidates in a strain of mice that develops Zika symptoms. One candidate, a DNA vaccine, was developed by Barouch and colleagues. It contains bits of genetic material from a Zika virus strain from Brazil. The other was made from a purified but inactivated version of the Zika virus from Puerto Rico. That vaccine was developed by researchers at Walter Reed Army Institute of Research in Silver Spring, Maryland. Mice given either type of vaccine were 100 per cent protected from Zika after a single shot. Unvaccinated mice that were exposed to the virus all developed symptoms of Zika. Both types of vaccines - DNA and inactivated virus vaccines - have been successfully developed to prevent infection from viruses related to Zika, including West Nile and dengue. The team also showed that antibodies taken from immunized mice could be used to protect other, unvaccinated mice, offering proof that the antibodies produced by the vaccines were specific to Zika. "We need to be cautious about extrapolating data from a mouse model into humans," Barouch said. But the fact that the vaccines protected mice and that their antibodies protected other mice from Zika was grounds for optimism over the development of a Zika vaccine, he said. At least 15 companies and academic groups are racing to develop Zika vaccines, according to the WHO. US vaccine maker Inovio Pharmaceuticals last week got US Food and Drug Administration approval to begin testing its Zika DNA vaccine in humans. Oxford University's Hill stressed that there are still years of testing needed before a finished vaccine will be available for humans. MONKEY INFECTION In another advance, researchers at the University of Wisconsin reported on Tuesday that they have successfully infected rhesus macaques with an Asian strain of the Zika virus that is currently circulating in the Americas. The study, published in the journal Nature Communications, shows that monkeys - which have immune responses similar to humans - can be used to study Zika. In the study, David O'Connor and colleagues inoculated eight rhesus macaques - including two pregnant monkeys - with a strain of Zika virus currently circulating in the Americas. All eight animals were infected. Tests showed viral particles in their blood, saliva, urine and spinal fluid. All animals stayed infected for at least 21 days, and some remained infected for at least 57 days. A second exposure to Zika 10 weeks after the first did not make the animals sick, suggesting that antibodies developed by the monkeys protected them against a second case of Zika. This is a promising sign that humans may similarly be able to develop protective antibodies against the virus. The scientists are still working to understand whether the pregnant monkeys will pass the infection along to their fetuses, and whether infected monkeys can transmit the virus sexually, as has been seen in infected humans. US health officials have concluded that Zika infections in pregnant women can cause microcephaly, a birth defect marked by small head size that can lead to severe developmental problems in babies. The WHO has said there is strong scientific consensus that Zika can also cause Guillain-Barre, a rare neurological syndrome that causes temporary paralysis in adults. (Reuters)

Zika vaccine tests successful on mice

<div>Reserve Bank of India chief Raghuram Rajan on Monday defended his record in fighting inflation, and made a case for the&nbsp;monetary policy reforms he has championed, in his first public appearance since announcing that&nbsp;he will step down at the end of his tenure in September. 
 
In a speech, the outgoing&nbsp;governor of India&#39;s central bank, Reserve Bank of India,&nbsp;addressed critics who have accused him of keeping interest rates too high, saying they cannot &quot;have it both ways, want lower inflation as well as lower policy rates.&quot; 
 
 
&quot;The fact that inflation is fairly close to the upper bound of our target zone today suggests we have not been overly hawkish&nbsp;and were wise to disregard advice in the past to cut more deeply,&quot; Rajan said.</div>

<div> 
Consumer inflation hit a near two-year high of 5.76 per cent in May, or the upper end of the central bank&#39;s inflation target of 2 per cent to 6 per cent. 
 
Rajan also strongly defended the upcoming introduction of a monetary policy panel to set interest rates,&nbsp;a policy he has championed,&nbsp;saying &quot;the rewards will be many&quot;, including a more stable policy framework. 
 
(Reuters)</div>

Tells critics of his monetary policy reforms they can't have it 'both ways'

Reserve Bank of India chief Raghuram Rajan on Monday defended his record in fighting inflation, and made a case for the monetary policy reforms he has championed, in his first public appearance since announcing that he will step down at the end of his tenure in September. In a speech, the outgoing governor of India's central bank, Reserve Bank of India, addressed critics who have accused him of keeping interest rates too high, saying they cannot "have it both ways, want lower inflation as well as lower policy rates." "The fact that inflation is fairly close to the upper bound of our target zone today suggests we have not been overly hawkish and were wise to disregard advice in the past to cut more deeply," Rajan said. Consumer inflation hit a near two-year high of 5.76 per cent in May, or the upper end of the central bank's inflation target of 2 per cent to 6 per cent. Rajan also strongly defended the upcoming introduction of a monetary policy panel to set interest rates, a policy he has championed, saying "the rewards will be many", including a more stable policy framework. (Reuters)

Out not down: Indian central bank governor Raghuram Rajan defends his record

both

Both, News on Both, stories on Both, articles on Both, Both stories at Wion, Both news, Both latest news